Brought to you by 
Chugai licenses diabetes project CSG452 to Kowa, Sanofi
29 Sep 2021
Executive Summary
Roche unit Chugai Pharmaceutical Co. Ltd. has granted Sanofi KK and Kowa Co. Ltd. rights to develop and co-market the Type II diabetes compound CSG452 in Japan.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chugai licenses diabetes project CSG452 to Kowa, Sanofi
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice